2025 SPS Puerto Rico | An Expanding Bispecifics Armamentarium: Zanidatamab Clinical Review and Considerations
Overview
Dr. Adriana Soto, presented data on Zanidatamap, a bispecific antibody approved by the FDA for treating HER2-positive biliary tract cancer. The therapy demonstrated a 41.3% objective response rate and 12-month overall survival in a phase 2 trial, with common side effects including diarrhea, infusion reactions, and elevated liver enzymes. Presented at 2025 SPS Puerto Rico.
Target Audience
Pharmacists
This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.
Faculty
Adriana E. Soto Avilés, PharmD, BCPS
Date of Release
June 13th, 2025
-%20Less%20is%20More-1749834394770.webp&w=3840&q=75)